LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

VANCOUVER, BC / ACCESS Newswire / June 17, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion of its comparative mouse study (the "Study") evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies1. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules.

Raccontata damorningstar.com